Biochemical Pharmacology 1992: Vol 43 Index

42 Pages·1992·13.6 MB·English

Biochemical Pharmacology
(FOUNDED BY SIR RUDOLPH A. PETERS)
SUBJECT INDEX FOR VOLUME 43, 1992
PREPARED BY W. COCKS
Pergamon Press 3, ‘.0"
(ow
Seoul : Tokyo
BIOCHEMICAL PHARMACOLOGY
EDITORIAL BOARD
Chairman: A. D. WELCH
Regional Editors
European Continent
Prof. PETER ALEXANDER Biochemical Pharmacology U.K. Office, P.O. Box 11,
(Executive Editor) Cullompton, Devon EX15 1TQ, U.K.
Prof. J. GIELEN Université de Liége, Laboratoire de Chimie Médicale, Insti-
tut de Pathologie, B-4000 Sart-Tilman par Liége 1, Belgium
Associate Editors
Prof. MARTIN K. CHURCH Clinical Pharmacology, Centre Block, Southampton General
Hospital, Southampton SO9 4XY, U.K.
Dr. PIERRE LADURON Département de Biologie, Rhéne-Poulenc Santé, Centre de
Recherches de Vitry, 13, quai Jules Guesde, 94403 Vitry sur
Seine, France
American Continent
Prof. ALAN C. SARTORELLI Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Associate Editors
Prof. YUNG-CHI CHENG Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Prof. PRISCILLA S. DANNIES Yale University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Prof. R. H. ROTH Yale ,University School of Medicine, Department of
Pharmacology, Sterling Hall of Medicine, 333 Cedar Street,
P.O. Box 3333, New Haven, Connecticut 06510-8066, U.S.A.
Commentaries Editor
Prof. C. NORMAN GILLIS Yale University School of Medicine, Departments of Anes-
thesiology and Pharmacology, Sterling Hall of Medicine, 333
Cedar Street, P.O. Box 3333, New Haven, Connecticut
06510-8066, U.S.A.
Production Editors (Pergamon): Priscilla Goldby and Suzanne Fox
Publishing and Advertising Offices: Headington Hill Hall, Oxford OX3 OBW (Oxford
794141), and 660 White Plains Road, Tarrytown, NY 10591-5153. Published two issues per
month. Annual Institutional Subscription Rate (1992) £1410.00 (US$2560.00). Two-year
Institutional Rate (1992/93) £2679.00 (US$4864.00). Sterling prices are definitive.
US dollar prices are quoted for convenience only, and are subject to exchange rate
fluctuation. Prices include postage and insurance and are subject to change without notice.
Subscription rates for Japan are available on request. Personal subscription rate for those
whose library subscribes at the regular rate is available on request. Subscription enquiries
from customers in North America should be sent to: Pergamon Press Inc., 660 White Plains
Road, Tarrytown, NY 10591-5153, U.S.A., and from the remainder of the world to:
Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 OBW, U.K.
Whilst every effort is made by the publishers and editorial board to see that no inaccurate or
misleading data, opinion or statement appears in this journal, they wish to make it clear that the
data and opinions appearing in the articles and advertisements herein are the sole responsibility of
the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and editors
and their respective employees, officers and agents accept no responsibility or liability whatsoever
for the consequences of any such inaccurate or misleading data, opinion or statement.
Second Class Postage paid at RAHWAY, NJ. Postmaster send address corrections to Pergamon
Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, U.S.A.
Copyright © 1992 Pergamon Press Ltd
Printed in Great Britain by BPCC Wheatons Ltd, Exeter 252
EDITORIAL ADVISORY BOARD
American Continent
7 AXELROD—National Institutes of Health, Bethesda, YUTAKA KoBAYASHI—Ko-By Associates, 60 Audubon Road,
Wellesley, MA
MICHAEL R. BoyD>—LDDRD, Developmental Therapeutics WaLTER M. LovENBERG—Marion Merrell Dow Research
Program, National Cancer Institute, Frederick, MD Institute, Cincinnati, OH
EDWARD Bresnick—Department of Pharmacology and Toxi- P. N. MaGEE—Thomas Jefferson University, Cancer Institute,
cology, Dartmouth Medical School, Hanover, NH Philadelphia, PA
D. N. BRINDLEY—Faculty of Medicine, University of Alberta, G. J. MANNERING—Department of Food Science and
Edmonton, Canada Nutrition, University of Minnesota, St. Paul, MN
MICHAEL J. BROWNSTEIN—National Institutes of Health, Tac E. MAnsour—Department of Pharmacology, Stanford
Bethesda, MD University Medical Center, Stanford, CA
Jack R. Cooper—Yale University School of Medicine, New PauL B. McCay—Oklahoma Medical Research Foundation,
Haven, CT Oklahoma City, OK
JAMES K. CowarD—College of Pharmacy, University of
HERBERT Y. MELTZER—Case Western Reserve University,
Michigan, Ann Arbor, MI Cleveland, OH
IAN CreEsE—Center for Molecular and Behavioral Neuro-
EsTEBAN Mezey—Johns Hopkins University School of
science, Aidekman Research Center, Newark, NJ
Medicine, Baltimore, MD
JOHN W. DaLy—National Institutes of Health, Bethesda, MD DaniEL W. NeBert—Department of Environmental Health,
Erwin G. Erpés—Department of Pharmacology, University
University of Cincinnati, Cincinnati, OH
of Illinois, College of Medicine, Chicago, IL
CHARLES A. NicHoL—Cannam Enterprises, 1508 Ward Street,
“— ERECINSKA—University of Pennsylvania, Philadelphia,
Durham, NC
A
RosertT E. Parks, JR—Brown University, Providence, RI
Ray W. FuLLER—Lilly Research Laboratories, Indianapolis,
GABRIEL L. PLAA—University of Montreal, Quebec, Canada
IN
EUGENE RoBerts—City of Hope Medical Center, Duarte,
RosBert C. GALLO—National Institutes of Health, Bethesda,
CA
MD
JEROME A. RotH—State University of New York, Medical
JAMES R. GILLETTE—National Institutes of Health, Bethesda,
Center, Buffalo, NY
RoBertT I. GLAZER—Georgetown University, Washington, DC CHARLES O. RUTLEDGE—School of Pharmacy, Purdue Univer-
I. Davin GOLDMAN—Medical College of Virginia, Richmond, sity, West Lafayette, IN
VA Boris TABAKOFF—University of Colorado School of Medicine,
Denver, CO
THEODORE E. GRAM—1036 Welsh Drive, Rockville, MD
M. R. HANLEY—School of Medicine, University of California, JOHN F. TALLMAN—Neurogeu, 35 Northeast Industrial Road,
Davis, CA Branford, CT
G. H. Hitcuincs—Wellcome Research Laboratories, Research SNoRRI Sv. THORGEIRSSON—National Institutes of Health,
Triangle Park, NC Bethesda, MD
Louis J. IGNARRO—UCLA School of Medicine, Department MARTHA VAUGHAN—National Institutes of Health, Bethesda,
of Pharmacology, Los Angeles, CA MD
WILLIAM B. JAKoBy—National Institutes of Health, Bethesda, NORMAN WEINER—University of Colorado Health Sciences
MD Center, Denver, CO
Davip G. JoHNs—National Institutes of Health, Bethesda, ARNOLD D. WELCH (Chairman)—Frederick Cancer Research
MD Facility of National Cancer Institute, Frederick, MD
HAROLD KALANT— University of Toronto, School of Medicine, JOHN R. WILLIAMSON—University of Pennsylvania, Philadelphia,
Toronto, Ontario, Canada PA
European Continent
F. M. BELPAIRE—J. F. and C. Heymans Instituteo’ f Pharma- G. MILLIGAN—Department of Biochemistry, University of
cology, Rijksuniversity, Ghent, Belgium Glasgow, Glasgow, U.K.
A. G. H. BLAKELEY—Department of Physiology, The Univer- P. Mo_pEus—Department of Toxicology, Karolinska Insti-
sity, Leicester, U.K. tute, 104 01 Stockholm 60, Sweden
K. W. Bock—Institute of Toxicology, Tiibingen University, G. J. MuL_peER—Department of Toxicology, University of
F.R.G. Leiden, Sylvius Laboratories, P.O. Box 9503, 2300 RA
J. CALDWELL—St. Mary’s Hospital Medical School, London, Leiden, The Netherlands
K. J. NETTER—Department of Pharmacology and Toxicology,
R. A. J. CHALLIss—Department of Pharmacology, University Philipps University, Marburg, Germany
of Leicester, Leicester, U.K. H. Nout—Institute of Pharmacology and Toxicology, Uni-
T. A. Connors—MRC Toxicology Unit, Carshalton, Surrey, versity of Vienna, Vienna, Austria
U.K. A. J. Paine—St Bartholomew’s Hospital Medical School,
E. De CLERcQ—Rega Institute for Medical Research, Univer- London, U.K.
sity of Leuven, Belgium B. K. PankK—Department of Pharmacology and Therapeutics,
J. Frere—lInstitute de Chimie, Université de Liége, Liége, University of Liverpool, Liverpool, U.K.
Belgium E. Reip—Guildford Academic Associates, Guildford, Surrey,
T. GoDFRAIND— Université Catholique de Louvain, Belgium U.K.
R. J. GRYGLEwski—School of Medicine, Cracow, Poland E. REINER—Yugoslav Academy of Sciences and Arts, 4100
J. HAMON—INSERM U288, Neurobiol Cellulaire et Fonc- Zagreb, Yugoslavia
tionnelle, Faculté de Medecine Pitie-Salpetriere, 91 Blvd de A. G. REeNwick—University of Southampton, Faculty of
lHOpital, F-75634 Paris Cedex 14, France Medicine, Southampton, U.K.
J. HANOUNE—INSERM U99, Hopital Henri Mondor, Creteil, P. J. RopErts—Department of Physiology and Pharmacology,
France Medical and Biological Sciences Building, Southampton,
J. A. HickMAN—Department of Physiological Sciences, U.K.
University of Manchester, Manchester, U.K. M. SANDLER—Bernhard Baron Memorial Research Labora-
I. JANkU—Institute of Pharmacology, Czechoslovak Academy tories, Queen Charlotte’s Maternity Hospital, London, U.K.
of Sciences, Czechoslovakia H. Sits—lInstitut fiir Physiologische Chemie 1, Universitat
P. JENNER—Department of Pharmacology, King’s College, Diisseldorf, Diisseldorf, Germany
London SW5 8AF, U.K. J. SkopA—Institute of Organic Chemistry and Biochemistry,
H. Kappus—Freie Universitat Berlin, Germany Czechoslovak Academy of Sciences, Prague, Czechoslo-
J. LunpBERG—Department of Pharmacology, Karolinska vakia
Institutet, Stockholm, Sweden B. Testa—Department of Pharmacy, University of Lausanne,
G. P. MANNAERTS—Dienst Farmakoligie, Campus Gasthuis- Lausanne, Switzerland
berg, Onderwijs en Navorsing, Herestraat, 3000 Leuven, K. Tipton—Department of Biochemistry, University of
Beigium Dublin, Trinity College, Ireland
D. Mansuy—Universite Renée Descartes, Laboratoire de V. Uccrich—Fakultat fiir Biologie, Universitat Konstanz,
Chimie et de Biochemie, Pharmacologiques et Toxicolo- Konstanz, Germany
giques, 45 rue des Saints-Péres, 75270 Paris Cédex 05, D. C. U’PricHARD—ICI Pharmaceuticals, Research II Dept,
France Mereside Alderley Park, Macclesfield, Cheshire, U.K.
A. E. M. McLean—Department of Clinical Pharmacology, P. WALDMEIER—Ciba-Geigy Limited, CH-4002 Basle, Switzer-
University College Hospital Medical School, London, land
U.K. M. B. H. Youpim—Technion-Israel Institute of Technology,
C. J. MeapE—Department of Pharmacology, Boehringer Faculty of Medicine, Department of Pharmacology, Bat
Ingelheim KG, D-6507 Ingelheim am Rhein, F.R.G. Galim, Haifa, Israel
Asia and Pacific Rim
K. KurivAMA—Kyoto Prefectural University of Medicine, T. WataBE—Tokyo College of Pharmacy, Tokyo, Japan
Kyoto, Japan
AIMS AND SCOPE
BIOCHEMICAL PHARMACOLOGY is an international journal which publishes research findings in pharmacology
deriving from investigations that employ the disciplines of biochemistry, biophysics, molecular biology, genetics,
structural biology, computer models and/or physiology. Reports of studies with intact animals, organs, cells,
subcellular components, enzymes or other cellular molecules and model systems are acceptable if they define
mechanisms of drug action. Descriptive mathematical models including those involving computer techniques are
also welcome. Experiments involving the use of drugs to elucidate physiological and behavioral mechanisms in
living organisms are also within the scope of the journal. In general, papers which record concentrations of drugs
and metabolites in body fluids will only be accepted if they contribute to an understanding of biochemical and
biophysical mechanisms. The Editors, however, reserve the right to publish any papers of major interest in the
field. Only contributions in English can be considered or published.
The journal publishes the following types of communication:
(1) Full-length Papers. These consist of a body of work presenting original findings relating to the question
proposed by the investigators undertaking the research.
(2) Short Communications. These consist of an original body of work of narrower scope but of the same quality
as the above. By definition, these papers are shorter than full-length manuscripts.
(3) Rapid Communications. These promote rapid dissemination of timely and significant observations within
the scope of the journal. Manuscripts must be submitted in English and will be judged as appropriate for
publication as rapid communications on the basis of their immediate importance. They should be written to
emphasize clearly the novel aspects of the research. These criteria will be applied strictly. In order to speed up
the publication of rapid communications, authors are encouraged to use the special laysheets available from any
of the Regional Editors.
(4) Commentaries are short commissioned review articles (3000-5000 words in length). They are designed to
be editorial statements on selected topics, and should not be exhaustive reviews. Primarily, Commentaries are
intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity,
or draw attention to relatively neglected fields in which there are both the opportunity and the need for research
in biochemical pharmacology. Particularly welcome will be Commentaries in which authors present their personal
view on the state of the subject on which they are reporting, and give their view as to where in the near or distant
future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas. The
Commentary series is edited by Professor C. Norman Gillis.
In order to increase the exchange of information and ideas, the Journal will also publish Comments on a
Commentary, in which selected, highly qualified authorities are invited to offer their own observations on
Commentary articles, which will be published in the same issue of the Journal, and thus provide some alternative
thoughts on important areas of research. For further information see Biochem Pharmacol 31, 2568 (1982).
While the final decision on selection of authors for either Commentaries or Comments on a Commentary will
be made at the discretion of the editor, suggestions from readers will be welcome. These should be addressed
to: Professor C. N. Gillis, Department of cet Haag Yale University School of Medicine, 333 Cedar Street,
New Haven, Connecticut 06510.
(5) Meeting Reports. The journal is prepared to publish as preliminary communications short, factual two-page
summaries of selected papers from small meetings or conferences. The meetings should be those where attendance
is by invitation and all papers to be published will be refereed. Organizers who wish to have their meetings
published in this way should contact the appropriate Regional Editor.
Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7
BIOCHEMICAL PHARMACOLOGY
SUBJECT INDEX FOR VOLUME 43, 1992
Absinthe 1-Acylglycerophosphocholine acyl-
porphyrogenicity of thujone 2359 transferase(contd. )
Accutane 2289 sterone 1269
Acetaldehyde-protein adducts AD 32
modification of cytotoxicity 407 inhibition of protein kinase C in
Acetaminophen human leukemia cells 865
glucuronidation in isolated liver Adenosine analogues
cells 971 adenosine receptor agonists 1089
N-Acetyl-p-benzoquinone imine Adenosine antagonists
induced protein thiol modification brain penetration 889
in hepatocytes 1493 Adenosine diphosphate/adenosine tri-
Acetylcholine phosphate transporter
depolarization of airway smooth in Plasmodium falciparum 71
muscle 29 Adenosine-3',5'-monophosphate
Acetylcholinesterase in adrenocortical cells, effects of
Electrophorus electricus, protection substance P and ACTH 513
by tetrahydroaminoacridine 2427 Ca2+ interaction, role in amylase
heart 823 secretion 1031
Acetyl-CoA in cultured aorta smooth muscle
in liver, effect of tilorone 1643 cells, effect of aging 1811
N-Acetylcysteine in endothelial cells, nitric oxide
restoration of depleted glutathione and prostacyclin effects 533
in liver mitochondria 961 in 3T3 fibroblasts, effect of
(N-3-Acetyl-4-5-dihydro-2-fura)n -yNl4 - griseolic acid analogues 2073
(methoxy-8-quinolinyl)1,4-pentane- in heart, effect of alloantibody
diamine 2493
effect on hepatic drug metabolizing in platelets, effect of dicentrine
enzymes 904 323
N-Acetyltransferases in thyroid cells, effect of bromo-
in blood, effect of tilorone 1643 levamisole 1507
in kidney, effect of tilorone 1643 Adenosine receptors Al
in liver in fat cell membranes, agonists
group-selective modification 2255 1089
effect of tilorone 1643 Adenosine receptors A2_.
#-Acid glycoprotein in PCl12 cell membranes, agonists
P-adrenergic ligand binding 725 1089
aj-Acid glycopr—o dticeouimanro l Adenosine triphosphatase
complex in P.falciparum, role in chloro-
effect of protriptyline 2161 quine sensitivity 1219
Acidosis Ca2+-Adenosine triphosphatase
effect on iron delocalization from in cardiac sarcolemma, inhibition
brain homogenates 979 by calmodulin antagonists 1/797
Aclacinomycin in liver endoplasmic reticulum,
uptake in K562 cells 2575 effect of ciprofibrate 595
Acrylamide Mg2+-Adenosine triphosphatase
neurotoxicity, effect of glutathione in leukemia cells, modulation by
modulation 263 P cholesterol and ether lipids 803
Acyl-CoA hydrolases Na -Adenosine triphosphatase
differential inhibition by hypo- in kidney proximal tubular cells,
lipidemic drugs 639 ffect of ethanol 2034
Acyl glucuronides Nat,K -Adenosine triphosphatase
reactivity 745 in kidney proximal tubular cells,
1-Acylglycerophosphocholine acyl- effect of ethanol 2034
transferase in leukemic cells, modulation by
in liver, effect of dehydroepiandro- cholesterol and ether lipids 803
BIOCHEMICAL PHARMACOLOGY
heESabiEae Sna B I
Adenosine triphosphate Aging
NSC INN
dependence of chloroquine accumul- p-adrenergic responsiveness in
ation and efflux in P.falciparum cultured aorta smooth muscle
at cells 1811
novel route of synthesis 2053 effect on liver response to vaso-
uptake by kidney mitochondria, active drugs 913
effect of cyclosporine A 1021 AHR-16303B 39 RTaAaCsSeeheea i as e
Adenosine triphosphate/adenosine di- Airway smooth muscle
phosphate ratio internal calcium store 29
relationship with insulin release muscarinic regulation of ion channels
1859 5
S-Adenosylhomocysteine hydrolase Albumin, human serum
ATP synthesis in erythrocytes 2053 copper complexes 137, 1601
Adenylate cyclase phenylbutazone binding 931
in liver, effect of bromolevamisole tryptophan binding 1829
1507 Alcohol
in PC12 cells, effect of adenosine effect on expression of cytP450 IIEl
analogues 1089 during human fetal development
in retina, effect of CV 205-502 1882 1876
in S49 cells, inactivation rate 2015 Alcohol dehydrogenase
in thyroid, effect of bromolevimasole in rat tissues during development
1505 1555
Adenylate translocase Alcohol dehydrogenase negative/positive
in P.falciparum 71 deermice
Adrenal gland retinoid dehydrogenases in testes
angiotensin II receptor subtypes in cytosol 2296
glomerulosa cells 1009 Alcoholic liver disease
benzodiazepine acceptor, effect of antioxidant activity of propylthio-
phospholipids 1939 uracil 439
cortisol secretion induced by Aldehyde dehydrogenase
substance P 513 chlorpropamide-induced inhibition
inositol hexakisphosphate binding to in vivo, effect of glutathione
chromaffin cell membranes 1331 and cysteine prodrugs 916
Adrenaline in human liver, aldophosphamide and
binding to Al-acid glycoprotein 725 retinaldehyde oxidation 2453
inositol hexakisphosphate induced in rat liver, inhibition by S-methyl
release from chromaffin cells ama ia lat a sulfoxide
1331
B-Adrenergic ligands Aldehyde oxidase
binding to al-acid glycoprotein 725 in liver
p-Adrenoceptors azoreductase activity 2227
in cultured aorta smooth muscle cells, conversion of 5-iodo-2-pyrimidin-
effect of aging 1811 one-2'-deoxyribose to 5-iodo-
in myocardial cells, effect of Ca2t deoxyuridine 2269
and Ca2+-antagonist 213 Aldophosphamide
partial agonism 119 oxidation by human liver aldehyde
in S49 cells, G protein encounter dehydrogenase 2453
frequency 2015 Aldosterone
Adrenocorticotropic hormone production by adrenal glomerulosa
induced cortisol secretion 513 cells, effect of angiotensin II
Adriamycin antagonists 1009
effect on hepatoma H-35 cells 331 Alkaline phosphatase
resistant CHO cells, mitomycin cross- in thyroid membranes, effect of
resistance 685 imidazo(1,2-b)thiazoles 1507
toxicity in heart 831 06-Alkylguanine-DNA alkyltransferase
toxicity in intestine 831 in colon cancer
effect of cycloheximide 1683 chlorozotocin resistance 1159
toxicity in liver 831 nitrosourea resistance 1101
uptake in K562 cells 2575 Allergic disorders
AF-DX 116 Neurotropin action 1361
effect on N-methylscopolamine Allopurinol
binding in colon smooth muscle effect on tumour necrosis factor
2413 release in endotoxin treated
Aflatoxin Bl mice 1151
effect of pigeon pea protease inhib- All-trans-retinoic acid
itor on genotoxicity 1880 conceptual biotransformation in rat
Age embryo culture 2289
effect on eicosanoid production in Allyl alcohol
guinea pig blood 837 induced lipid peroxidation in
3a-hydroxysteroid/dihydrodiol hepatocytes, effect of IdB 1016
dehydrogenase in rat liver cytosol 2111
1148 Ametantrone
Aging reduction by DT-diaphorase ato
BIOCHEMICAL PHARMACOLOGY 3
Amine oxidases Androstenedione
semicarbazide-sensitive, vascular metabolism in liver microsomes from
aminoacetone metabolism 1409 female rats, effect of interferon
inhibition by MDL-72974A 307 908
Aminoacetone Androstenedione hydroxylase
metabolism by semicarbazide-sensitive in liver microsomes, effect of
amine oxidase in umbilical cyclophosphamide 2655
artery 1409 Angiotensin II
¥-Aminobutyric acid receptor subtypes in adrenal
in brain glomerulosa cells 1009
effect of phenelzine 2486 Angiotensin converting enzyme
effect of vigabatrin 2143 in lung, effect of nitrofurantoin
¥-Aminobutyric acid transaminase 1127
in brain Angiotensinogen
effect of phenelzine 2486 transgenic studies 929
effect of vigabatrin 2143 Anguidine
7-Aminocephalosporanic acid effect on protein synthesis in
inactivation of placental glutathione reticulocyte lysate 1/1/
S-transferasetr 1757 Aniline hydroxylase
8-(4-(((((2-Amino-ethyl)amino)carbonyl ) in liver microsomes
methyl )oxy)phenyl)1,3-dipropyl- fasting suncus 1907
xanthine effects of primaquine and
brain penetration 889 compound 80/53 904
N-(6-Aminohexyl1 )-5-chloro-1l-naphthalene 1-Anilino-8-naphthalene sulfonate
sulfonamide binding to e&l-acid glycoprotein 725
inhibition of substance P-induced Anion transport inhibitors
cortisol secretion 513 effect on eosinophil respiratory
5-Aminolevulinic acid synthase burst 2480
in chick embryo liver, effect of Anoxia
terpenes 2359 effect on iron delocalization from
in rat liver, effect of carbamazepine brain homogenates 9/79
1473 effect of potassium channel modulat-
4-Aminopyridine G28 .-1i
inhibition of potassium channel 11 Anthelmintics
Aminopyrine demethylase benzimidazole toxicity 1095
in liver microsomes Anthracyclines
effect of 4-benzylpyridine 2151 uptake in K562 cells 2575
effect of cyclophosphamide 2655 Anthracyclines/Fe(III)
effects of primaquine and effect on lipid peroxidation,
compound 80/53 904 phosphoinositide turnover and
uremic rats 2407 protein kinase c in platelets
Aminosalicylates 1521
radical scavenging 259 Anthraquinones
5-Aminosalicylic acid reduction by DT-diaphorase 575
effect on prostaglandin production Anti-allergic drugs
by mononuclear cells 2369 effect on neutrophil NADPH oxidase
Amiodarone 1109
lipid interactions and photooxidation Anticancer drugs
2559 hepatocyte toxicity 1963
Amisulpride 659 Anticoagulant
Amitriptyline fucoidan 1853
complexation of cytochrome P450 2065 Antidepressant drugs
effect on 5-HT uptake by rat and complexation of cytochrome P450
guinea pig brain 1865 2065
Amlodipine 39 effect on GABA in brain 2486
Amodiaquine Antiestrogen binding site
action and resistance 63 in liver, ligand specificity 2511
metabolism in rat 1421 Antimalarial drugs
d-Amphetamine effect on mefloquine metabolism by
effect on dopamine neuronal outflow human liver microsomes 1957
507 Antioxidants
m-AMSA effect on alkylating anticancer
effect on hepatoma H-35 cells 331 drug toxicity 1963
m-AMSA - netropsin hybrid ligand 45/7 IdB 1016 2111
Amylase in liver, effect of ciprofibrate and
secretion by parotid acinar cells, perfluorodecanoic acid 1353
calcium-cyclic AMP interaction Antipsychotic drugs
1031 D3 dopamine receptor as a target 659
Anatoxin-A Aorta
homoanatoxin 419 aging and B-adrenergic responsiveness
Androgen receptor in cultured smooth muscle cells
antihormone action 2299 1811
Androstenedione effect of glutathione S-transferase
4 BIOCHEMICAL PHARMACOLOGY
Aorta(contd. ) Atropine(contd. )
inhibitors on glyceryl trinitrate in colon smooth muscle 2413
relaxation 2247 Auranofin/eicosapentaenoic acid
myosin light chain phosphorylation inhibition of leukotriene B4
and endothelin-1l secretion from synthesis 695
endothelial cells 1/701 Autoreceptors
P2 receptors and phospholipase in D3 dopamine receptor 659
endothelial cells 1235 Azelastine
semicarbazide-sensitive amine effect on neutrophil NADPH oxidase
oxidase, inhibition by MDL-72974A 1109
307 Azidobenzoyl-daunorubicin
thromboxane A2 receptors in endo- P-glycoprotein labelling 89
thelial cells 1/747 3'-Azido-3'-dideoxythymidine
Apolipiprotein AI effect on Friend murine erythroleuk-
secretion by Hep G2 cells, effect emia cells 1397
of fibrates 625 ‘glucuronidation by human liver
Apolipoprotein B UDP-glucuronosyltransferase 382
secretion by HepG2cells, effect of Azidoprocainamide methiodide
fibrates 625 hepatic uptake 2217
Apoptosis Aziridinylbenzoquinones
adriamycin induced cell death 1683 induced DNA crosslinks 1249
Arachidonic acid metabolism by DT-diaphorase 1657
metabolism in mononuclear cells, Azo dye sudan III
effect of diethyldithiocarbamate induction of propranolol metabolism
1339 in rats 2489
in serum, reduction by clofibric Azoreduction
acid 2321 by aldehyde oxidase 2227
D-Arg-containing dipeptides and
tetrapeptides
opioid properties eu? Bafilomycin Al
Aroclor-1254 effect on chloroquine uptake by
effect on lauric acid hydroxylase in P.falciparum 1219
liver microsomes 2621 Basement membrane components
effect on UDP-glucuronosyltransfer- effect on tumorigenicity of breast
ases in liver parenchymal and cancer cells 1263
nonparenchymal cells /731 Basophils
Artemisinin effect of flavonoids 1167
hemin-catalysed decomposition 1805 BAY K 8644
Artery effect on melphalan uptake by
aminoacetone metabolism by semi- L5178Y lymphoblasts 1154
carbazide-sensitive amine oxidase Benoxaprofen
1409 effect on neutrophil respiratory
semicarbazide-sensitive amine oxidase burst 413
inhibition by MDL-72974A 307 Benzafentrine
Arylhydrocarbon hydroxylase effect on inflammation and asthma
in monocytes of patients with liver 2041
disease 1163 Benzalazine
Arylhydrocarbon receptor radical scavenging 259
in C-4II cervical squamous carcinoma Benzene
cells 1635 cytochrome P450 isoenzymes involved
2-Arylpropionic acids in metabolism 251]
inhibition of long chain fatty acid Benzimidazole carbamates
CoA ligase 1465 binding to brain tubulin 1095
metabolic chiral inversion in Benzimidazole-2-thione derivatives
hepatoma cells 1487 binding to liver microsomes 881
Ascites hepatoma cells Benzodiazepine acceptor
drug resistance and P-glycoprotein peripheral type in adrenal gland,
size 1143 stabilization by phospholipids
ASM-5-10 1939
opioid receptor binding 301 Benzodiazepines
ASM- 5-67 metabolism by phenobarbitone-treated
opioid receptor binding 301 liver microsomes 13/77
Aspirin Benzoporphyrin-monoacid ring A
effect on neutrophil respiratory photosensitization with 2349
burst 413 Benzo(a)pyrene
Asthma effect on cysteine isopropylester
phosphodiesterase inhibitors 2041 toxicity 483
Atheysclerosis Benzotriazine di-N-oxide
Ca** channel activity 39 metabolism by DT-diaphorase 1657
Atrial natriuretic peptide Benzphetamine demethylase
transgenic studies 925 in chick embryo liver cells, effect
Atropine of terpenes 2359
effect on N-methylscopolamine binding B: ‘lamine
BIOCHEMICAL PHARMACOLOGY
Benzylamine Bradykinin B2 receptors
metabolism by umbilical artery, in ileum smooth muscle and mucosa
effect of aminoacetone 1409 1823
Benzyloxyresorufin Q-dealkylase Brain
in liver, effect of phenobarbital- development of alcohol dehydrogenase
type inducers 1067, 1979 1555
4-Benzylpyridine diethylmaleate-induced glutathione
and its analogues, induction of depletion 451
hepatic cytochrome P450 2151 glutathione modulation and acryl-
Betamethasone amide toxicity 263
induction of steroid esterase in hen, Ca2+/calmodulin-dependent
liver and serum 1921 protein kinase II 1975
Bezafibrate high affinity 5-HT uptake system, rat
inhibition of palmitoyl-CoA hydrol- and guinea pig 1865
ases 639 iron delocalization 979
Big-endothelin-1 penetration of adenosine antagonists
hydrolysis by mast cell chymase 845 889
Bile SCH23390 binding 1947
effect of ethinylestradiol and vinca alkaloid binding to tubulin
epomediol on lipid composition 545
1289 Breast cancer cells MDA-MB-231
inhibition of indocyanine green cisplatin analogue toxicity and
excretion by diazenedicarboxylic aqueous chemistry 2609
acid bis(N,N'-dimethylamide) 477 Breast cancer cells MCF-/7
Bile acid cisplatin analogue toxicity and
uptake into diploid and polyploid aqueous chemistry 2609
hepatocytes 1195 effect of 5-deazaacyclotetrahydro-
Bile flow folate analogues 1627
effect of ethinylestradiol and doxorubicin toxicity enhancement
epomediol 1289 1449
Bilirubin matrigel promotes tumouigenicity
glucuronidation in liver parenchymal 1263
and nonparenchymal cells 731 effect of netropsin-acridine hybrid
Bimakalim 4/7 ligand 457
BI-RG-587 Breast tumours CD8F1
inhibition of HIV-1 reverse trans- biochemical modulation of 5-fluoro-
criptase 13/71 uracil 2543
1,3-Bis-(2-chloroethyl)-1l-nitrosourea Bremazocine
effect on changes in hepatocyte binding in cerebellum, effect of
pyridine nucleotides produced by carbodiimide 1415
tert-butyl hydroperoxide 1119 Brequinar sodium
resistance in colon cancer, modulat- inhibition of dihydroorotate
ion by QO”’-methylguanine 1101 dehydrogenase/oxidase 1025
1,4-Bis-(2-(3,5-dichloropyridyloxy) - Brequinar sodium/hypoxia
benzene effect on tumour cell growth 2281
induction of mouse liver cytochrome Brij 58
P450 isozymes 2121 activation of UDP-glucuronosyltrans-
2,3-Bis(3-indolylmethyl)indole ferases in liver 1563, 1649
effect on cytochrome P450 and phase BRL 38227
Il enzymes in hepatocytes 1439 pharmacology 4/7
Bleomycin effect on phosphoinositide metabolism
DMA damage and growth inhibition 615 in tracheal smooth muscle 1/7
Blood flow 5-Bromo-2'-deoxyuridine
liver, age-related decline 913 metabolism in glioblastoma cells
Blood pressure 1579
endogenous vasodilator 47 Bromodexamisole
transgenic model 925 effect on adenylate cyclase 1507
BM 13505 and 13177 2-Bromoisovalerylurea
effect on thromboxane receptor glutathione conjugation in kidney
ligand binding in endothelial proximal tubular cells 902
cells 1747 Bromolevamisole
BMY-28565 effect on adenylate cyclase 1507
inhibition of melanogenesis 183 Bromotrichloromethane
Boron neutron-capture therapy induced lipid peroxidation in
2,4-divinyl-nido-o-carboranyldeutero- hepatocytes, effect of IdB 1016
porphyrin decarboxylase 46/7 2111
Bovine pancreatic trypsin inhibitor Bronchial asthma
as a probe of Ca2+-activated Kt phosphodiesterase inhibitors 2041
channels 21 Bronchorestriction
Bradykinin Ca2+ store in airway muscle 29
effect of Neurotropin on formation Bruceantin
1361 effect on protein synthesis in
Bradykinin B2 receptors reticulocyte lysate 1/717
6 BIOCHEMICAL PHARMACOLOGY
Bryostatin 4 Calcium antagonists
binding to protein kinase C 2007 effect on fB-adrenoceptors in myo-
Budesonide cardial cells 213
effect on testosterone metabolism by effect on glycolysis in synaptosomes
EAE
liver microsomes 271 371
Bufuranol modulation of drug transport by
in bovine and rabbit tissues 191l P-glycoprotein 2601
Buthionine sulfoximine effect on muscarinic receptors in
effect on acrylamide neurotoxicity myocardial cells 2327
263 tissue selectivity 55
effect on glutathione turnover in Calcium channels 1
channel catfish 2209 in cardiovascular disease 39
effect on nitroglycerin metabolism voltage-dependent, airway smooth
by vascular smooth muscle 561 muscle, muscarinic regulation 5
effect on prostacyclin and thromboxaneCalmidazolium
in rat tissues and plasma 1043 inhibition of Ca2+-ATPase from
effect on prostaglandin A2 cyto- cardiac sarcolemma 1/797
toxicity 1053 inhibition of substance P-induced
Butylated hydroxyanisole cortisol secretion 513
effect on alkylating anticancer drug Calmodulin
toxicity 1963 dependent protein kinase II in hen
effect on liver mitochondrial brain 1975
oxidative phosphorylation 1203 Calmodulin antagonists
t-Butyl hydroperoxide inhibition of cardiac sarcolemmal
hepatotoxicity, effect of chronic Ca2+-ATPase 1797
hypoxia 2421 inhibition of substance P-induced
effect on pyridine nucleotide metabol- cortisol secretion 513
ism in cultured hepatocytes 1119 Camphor
Butyrylcholinesterase porphyrogenicity 2359
in heart 823 Camptothecin
in serum, protection by tetrahydro- resistant Chinese hamster lung cells
aminoacridine 2427 2443
BW A4C Cancer cells
pharmacodynamics and selectivity in multidrug resistance 77, 89, 95,
guinea pig 37/7 103, 109
effect of vitamin D analogues 1885
Cancer chemotherapy
Cadmium DT-diaphorase 1657
effect on morphine glucuronidation Carbachol
20. tiwer £295 effect on phosphatidylinositol
Caenorhabditis elegans metabolism in pancreatic islets
paraherquamide binding 6/79 1303
Caffeine stimulated phosphoinositide metabol-
metabolism by single cytochrome P450s ism in tracheal smooth muscle,
225 effect of BRL 38227 17
Calcineurin Carbamazepine
specific inhibition by Type II effect on heme metabolism in rat
pyrethroids 1/7/77 liver 1473
Calcipotriol 1885 metabolism by liver microsomes 1675
effect on human megakaryoblastic Carbamylcholine-isoproterenol
leukemia cell line 2292 potentiation of amylase secretion
Calcitonin gene-related peptide 1031
cleavage of chemotactic factor by Carbodiimide
endopeptidase-24.11 1753 modification of opioid receptors
degradation by tryptase 1243 1415
Calcium Carbohydrate
effect on B-adrenoceptors in myo- effect on ethanol-induced lipid
cardial cells 213 peroxidation 245
cyclic AMP interaction, role in amyl- Carboplatin
ase secretion 1031 effect on expression of HIV-1 LTR
influx in chromaffin cells, effect 650
of inositol hexakisphosphate 1331 Cardiomyocytes
in liver, effect of ciprofibrate 595 guanine nucleotide regulation of
effect on melphalan uptake by L5178Y inositol 1,4,5-trisphosphate
lymphoblasts 1154 metabolism 1001
platelet activating factor catabolism Cardioprotective agents
by human colonic mucosa 2503 K channel openers 4/7
prooxidant induced release from liver Cardiovascular disease
mitochondria 961 calcium channels 39
role in Substance P-induced cortisol Carmustine
secretion 513 hepatocyte toxicity 1963
store in airway smooth muscle 29 Carnitine acetyltransferase
Calcium antagonists in liver, effect of dehydroepiandro-